Today
+1.05%
5 Days
-3.15%
1 Month
-2.34%
6 Months
+47.55%
Year to Date
+23.66%
1 Year
+66.09%
• CVS Health shares declined following an earnings report highlighting increased medical benefit ratios. • Management lowered full-year earnings guidance due to rising costs and retail pharmacy pressures. • Regulatory scrutiny regarding pharmacy benefit manager practices has introduced significant policy uncertainty.
• Thermo Fisher exceeded quarterly earnings estimates and raised full-year organic revenue guidance. • Increased pharmaceutical capital expenditure and demand for clinical services boosted the company's backlog. • Technical indicators suggest a buy signal with an average analyst price target of $634.52.
• Intuitive Surgical exceeded quarterly expectations, raising full-year guidance on high global procedure volumes. • Strong Da Vinci 5 platform adoption and recurring revenue streams drove institutional investor confidence. • Technical indicators show a sell signal, despite positive fundamental growth and market positioning.
• Stryker’s second-quarter earnings exceeded analyst expectations with growth in MedSurg and Neurotechnology. • Management raised full-year earnings guidance citing strong demand and elective procedure recovery. • Analysts increased price targets following positive performance and consistent robotic technology market expansion.
• Danaher’s quarterly earnings surpassed analyst expectations, driving a rise in the company’s stock price. • Bioprocessing demand has normalized, signaling a recovery in the company’s biotechnology and life sciences segments. • Management raised full-year earnings and revenue guidance, citing sustainable growth in core business units.
• UnitedHealth reported strong quarterly earnings driven by growth in its Optum health services segment. • Stable Medicare Advantage reimbursement rates have improved sentiment toward the managed care sector. • A resilient labor market and cooling inflation are supporting UnitedHealth's commercial insurance revenue.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.48% |
| BlackRock Institutional Trust Company, N.A. | 5.07% |
| State Street Investment Management (US) | 4.98% |
| Vanguard Portfolio Management, LLC | 2.65% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.13% |
| Investment Advisor/Hedge Fund | 26.02% |
| Research Firm | 3.63% |
| Pension Fund | 2.30% |
Related Instruments
Popular Instruments